Glancy Prongay Wolke & Rotter LLP announced a class action lawsuit against Replimune Group, Inc., alleging the company made false statements and withheld critical information about FDA study design issues and early trial data. These omissions allegedly misled investors about the company's prospects, potentially causing losses. Investors who suffered losses can participate or seek to be lead plaintiff by October 5, 2026. The law firm offers assistance to recover losses but no class has been certified yet.
A leading semiconductor exchange-traded fund (ETF) has delivered an impressive average annual return of 14% since 2001. Over the last twelve months alone, the ETF surged by 118%, highlighting strong growth in the chip sector. This performance undersc...
Zoomd Technologies Ltd. announced it will release its financial results for the second quarter of 2026 on August 31. The company will hold a conference call at 9:00 AM ET the same day to discuss the results and provide a corporate update. Zoomd is a ...
Elanco Animal Health has finished a $120 million expansion of its Elwood, Kansas manufacturing site, increasing monoclonal antibody production capacity by over four times. This expansion supports the production of innovative animal health treatments ...
Revolut has introduced EURR, a euro-pegged stablecoin issued under the EU's MiCA regulations through a Luxembourg-based entity owned by Stripe. Initially available to select customers in Denmark, Poland, and Portugal, EURR allows Revolut's 80 million...
AllianceBernstein lowered its price target for Strategy (formerly MicroStrategy) from $450 to $350, citing equity dilution and a tougher interest rate environment. Despite the cut, the firm maintained an outperform rating, believing in the long-term ...
